CN113215307A - 新型冠状病毒检测试剂 - Google Patents
新型冠状病毒检测试剂 Download PDFInfo
- Publication number
- CN113215307A CN113215307A CN202011539153.5A CN202011539153A CN113215307A CN 113215307 A CN113215307 A CN 113215307A CN 202011539153 A CN202011539153 A CN 202011539153A CN 113215307 A CN113215307 A CN 113215307A
- Authority
- CN
- China
- Prior art keywords
- novel coronavirus
- detection reagent
- enzyme
- reagent
- qrt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims abstract description 23
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 15
- 102000004190 Enzymes Human genes 0.000 claims abstract description 24
- 108090000790 Enzymes Proteins 0.000 claims abstract description 24
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims abstract description 12
- 238000011529 RT qPCR Methods 0.000 claims abstract description 12
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 6
- 230000028327 secretion Effects 0.000 claims abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种新型冠状病毒检测试剂，检测试剂包括HEK293‑hACE2细胞、PE标记的新型冠状病毒刺突糖蛋白S1、qRT‑PCR酶，使用时，所述PE标记的新型冠状病毒刺突糖蛋白S1的终浓度为0.3‑0.4ug/ml，qRT‑PCR酶包括Taq酶和UDG酶，试剂的检测样本包括呼吸道分泌物样本和血浆样本。本发明具有特异性强，灵敏度高、稳定性好，操作简单，实验室要求低以及安全性高等特点。
Description
技术领域
本发明涉及一种检测试剂，特别涉及一种新型冠状病毒检测试剂。
背景技术
冠状病毒是自然界广泛存在的一个大型病毒家族，因其形态在电镜下观察似王冠而得名，主要引起呼吸系统疾病。2020年2月11日，世界卫生组织宣布，将新型冠状病毒肺炎，正式命名为“COVID-19”，全称CoronavirusDisease2019。感染新型冠状病毒后，患者初始症状多为发热、乏力、干咳，并逐渐出现重症表现，部分严重病例可出现急性呼吸窘迫综合征或脓毒性休克，甚至死亡，该病暂时没有特效治疗方法。
发明内容
本发明的目的在于提供一种新型冠状病毒检测试剂。
本发明采用的技术方案是：
新型冠状病毒检测试剂，其特征在于：所述检测试剂包括HEK293-hACE2细胞、PE标记的新型冠状病毒刺突糖蛋白S1、qRT-PCR酶，使用时，所述PE标记的新型冠状病毒刺突糖蛋白S1的终浓度为0.3-0.4ug/ml。
所述qRT-PCR酶包括Taq酶和UDG酶。
所述试剂的检测样本包括呼吸道分泌物样本和血浆样本。
本发明的优点：具有特异性强，灵敏度高、稳定性好，操作简单，实验室要求低以及安全性高等特点。
具体实施方式
实施例1
新型冠状病毒检测试剂，检测试剂包括HEK293-hACE2细胞、PE标记的新型冠状病毒刺突糖蛋白S1、qRT-PCR酶，使用时，所述PE标记的新型冠状病毒刺突糖蛋白S1的终浓度为0.4ug/ml。
qRT-PCR酶包括Taq酶和UDG酶。
试剂的检测样本包括呼吸道分泌物样本和血浆样本。
实施例2
新型冠状病毒检测试剂，检测试剂包括HEK293-hACE2细胞、PE标记的新型冠状病毒刺突糖蛋白S1、qRT-PCR酶，使用时，所述PE标记的新型冠状病毒刺突糖蛋白S1的终浓度为0.4ug/ml。
qRT-PCR酶包括Taq酶和UDG酶。
试剂的检测样本包括呼吸道分泌物样本和血浆样本。
实施例3
新型冠状病毒检测试剂，检测试剂包括HEK293-hACE2细胞、PE标记的新型冠状病毒刺突糖蛋白S1、qRT-PCR酶，使用时，所述PE标记的新型冠状病毒刺突糖蛋白S1的终浓度为0.35ug/ml。
qRT-PCR酶包括Taq酶和UDG酶。
试剂的检测样本包括呼吸道分泌物样本和血浆样本。
本发明具有特异性强，灵敏度高、稳定性好，操作简单，实验室要求低以及安全性高等特点。
以上所述的实施例仅仅是对本发明的优选实施方式进行描述，并非对本发明的范围进行限定，在不脱离本发明设计精神的前提下，本领域技术人员对本发明的技术方案做出的各种变形和改进，均应纳入本发明权利要求书确定的保护范围内。
Claims (3)
1.新型冠状病毒检测试剂，其特征在于：所述检测试剂包括HEK293-hACE2细胞、PE标记的新型冠状病毒刺突糖蛋白S1、qRT-PCR酶，使用时，所述PE标记的新型冠状病毒刺突糖蛋白S1的终浓度为0.3-0.4ug/ml。
2.据权利要求1所述的新型冠状病毒检测试剂，其特征在于：所述qRT-PCR酶包括Taq酶和UDG酶。
3.根据权利要求1所述的新型冠状病毒检测试剂，其特征在于：所述试剂的检测样本包括呼吸道分泌物样本和血浆样本。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011539153.5A CN113215307A (zh) | 2020-12-23 | 2020-12-23 | 新型冠状病毒检测试剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011539153.5A CN113215307A (zh) | 2020-12-23 | 2020-12-23 | 新型冠状病毒检测试剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113215307A true CN113215307A (zh) | 2021-08-06 |
Family
ID=77085915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011539153.5A Withdrawn CN113215307A (zh) | 2020-12-23 | 2020-12-23 | 新型冠状病毒检测试剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113215307A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200384034A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| CN112079906A (zh) * | 2020-07-15 | 2020-12-15 | 张影 | 一种高稳定性新型冠状病毒刺突蛋白、相关生物材料及其应用、检测试纸和检测试剂盒 |
| CN112098660A (zh) * | 2020-11-03 | 2020-12-18 | 北京百普赛斯生物科技股份有限公司 | 新型冠状病毒中和性抗体检测试剂盒 |
-
2020
- 2020-12-23 CN CN202011539153.5A patent/CN113215307A/zh not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200384034A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| CN112079906A (zh) * | 2020-07-15 | 2020-12-15 | 张影 | 一种高稳定性新型冠状病毒刺突蛋白、相关生物材料及其应用、检测试纸和检测试剂盒 |
| CN112098660A (zh) * | 2020-11-03 | 2020-12-18 | 北京百普赛斯生物科技股份有限公司 | 新型冠状病毒中和性抗体检测试剂盒 |
Non-Patent Citations (2)
| Title |
|---|
| YUNLONG CAO等: "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells", 《CELL》, vol. 182, pages 73, XP086211425, DOI: 10.1016/j.cell.2020.05.025 * |
| 肖斌;周泉;雷婷;何咏茵;李林海;: "SARS-Cov-2实验室检测技术的应用及展望", 南方医科大学学报, no. 04, pages 603 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qiao et al. | Viral diarrhea in children in Beijing, China | |
| Wang et al. | Overview of Stachybotrys (Memnoniella) and current species status | |
| CN113005228B (zh) | 一种同步检测多项呼吸道病原体的检测试剂盒及其检测方法 | |
| Kaina | On the origin of SARS-CoV-2: did cell culture experiments lead to increased virulence of the progenitor virus for humans? | |
| CN113025748A (zh) | 一种快速检测新型冠状病毒69-70del突变的引物组合物及试剂盒 | |
| CN113462683B (zh) | 适用于多种样本核酸提取的无醇清洗液及核酸提取试剂盒 | |
| CN101899534A (zh) | 用于检测小鹅瘟病毒和番鸭细小病毒的试剂盒及其检测方法 | |
| Salimi-Jeda et al. | SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies | |
| CN113493856A (zh) | 一种用于冠状病毒检测分型的多重rt-pcr试剂盒、方法及引物组 | |
| US20230295750A1 (en) | Methods and reagents for detection of chikungunya virus and zika virus | |
| Delcuve et al. | SARS‐CoV‐2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities | |
| CN113215307A (zh) | 新型冠状病毒检测试剂 | |
| Tee et al. | Surveillance, isolation and genomic characterization of Pteropine orthoreovirus of probable bat origin among patients with acute respiratory infection in Malaysia | |
| CN113855654A (zh) | 一种预防和治疗冠状病毒感染的组合物 | |
| CN101086011A (zh) | 食用菌和植物双链rna病毒检测试剂盒及其应用 | |
| CN110551694B (zh) | 塞尼卡谷病毒svv/ch/zz/2016 | |
| CN114128723B (zh) | 一种抗病毒纳米材料及其应用 | |
| CN113736913B (zh) | 基于病毒核酸与miRNA双向共生检测2019-nCoV的方法及试剂盒 | |
| CN117279652A (zh) | 含黑参有效成分的预防、改善或治疗冠状病毒感染的组合物 | |
| CN1233843C (zh) | 大蒜病毒检测试剂盒及其检测方法 | |
| CN105067574A (zh) | Ev71 3c蛋白酶作用靶点检测试剂盒及检测方法 | |
| CN116920073B (zh) | 一种多肽在腹泻治疗中的应用及含该多肽的药物 | |
| CN100350055C (zh) | 一种定量检测传染性非典型肺炎冠状病毒拷贝数的试剂盒 | |
| CN114561448B (zh) | 病毒核酸样品处理液、试剂、提取方法及其应用 | |
| CN102140526A (zh) | 一种检测高致病性猪繁殖与呼吸综合征病毒变异株的试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210806 |